TY  - JOUR
AU  - Sartor, O
AU  - Heinrich, D
AU  - Mariados, N
AU  - Mendez Vidal, M J
AU  - Keizman, D
AU  - Thellenberg Karlsson, C
AU  - Peer, A
AU  - Procopio, G
AU  - Frank, S J
AU  - Pulkkanen, K
AU  - Rosenbaum, E
AU  - Severi, S
AU  - Trigo Perez, J M
AU  - Wagner, V
AU  - Li, R
AU  - Nordquist, L T
PY  - 2017
DO  - 10.1093/annonc/mdx331
UR  - http://hdl.handle.net/10668/11628
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - Six radium-223 injections at 4-week intervals is indicated for patients with castration-resistant prostate cancer and symptomatic bone metastases. However, patients usually develop disease progression after initial treatment. This prospective phase...
LA  - en
PB  - Elsevier
KW  - Bone metastases
KW  - Injections
KW  - Prostate
KW  - Radium-223
KW  - Re-treatment
KW  - Safety
KW  - Aged
KW  - Aged, 80 and over
KW  - Alkaline phosphatase
KW  - Bone neoplasms
KW  - Humans
KW  - Kallikreins
KW  - Male
KW  - Middle aged
KW  - Prospective studies
KW  - Prostate-specific antigen
KW  - Prostatic neoplasms, castration-resistant
KW  - Radium
KW  - Re-irradiation
TI  - Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.
TY  - research article
VL  - 28
ER  -